Health Bulletin 18/February/2022

Here are Top Health stories of the day

Hacking: Anti-hijab tweet on doc's account  

Dr Shantanu R Prabhu, a pediatrician in Ujire, said in a complaint that the anti-hijab tweet appeared on his account aimed at tarnishing his image, police sources said.

A Ujire doctor in Dakshina Kannada region has complained to police that his  twitter account has been hijacked by unscrupulous people who have posted anti-hijab inscriptions on it.

National Action Plan On Antimicrobial Resistance: NMC Directs Medical Colleges To Nominate Nodal Officers

Reminding the medical colleges about the growing threat of Antimicrobial Resistance (AMR), the NMC has recently written to the heads of the medical institutes to inform them about the National Action Plan (NAP), developed by the Union Ministry of Health and Family Welfare.

In the letter, the Officer Incharge of NAP-AMR of NMC, Dr. Vijaya Lakshmi Nag has directed the medical colleges to nominate One Nodal Officer, preferably at the level of Professor/ Addl. Professor from any of the Department of Microbiology, Pharmacology, Medicine or Community Medicine for future interaction/ discussions on the subject.

For more details, check out the full story on the link below:

National Action Plan On Antimicrobial Resistance: NMC Directs Medical Colleges To Nominate Nodal Officers

India reports outbreak of H5N1 bird flu - OIE

India 3 reported an outbreak of the highly contagious bird H5N1 virus on a poultry farm in the northeastern Bihar region, 3.1 The World Organization for Animal Health (OIE) said on Wednesday.

The virus has killed 787 of the 3,859 birds on a farm in Patna and killed the remaining 3.2 birds, the Paris-based OIE said, citing a report by Indian authorities.

Study: Breast cancer cases rise, cervical cancer dips

Sun Pharma gets CDSCO nod to market Tofacitinib to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis

In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.

This came after the drug maker Sun Pharma presented the proposal for manufacturing and marketing of Tofacitinib ER Tablets 11mg along with bioavailability (BE) Study report before the committee.

For more details, check out the full story on the link below:

 Sun Pharma Gets CDSCO Nod To Market Tofacitinib To Treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis